Phaseline

Companies › Antengene Biologics

Antengene Biologics: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology, Immunology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ATG-022
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3Advanced Gastric or Gastroesophageal Junction Adenocarcinoma; Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced/Metastatic Solid TumorsSep 2027
ATG-201
Bispecific T-cell engager (TCE) binding CD3 and CD19
CD3, CD19Phase 1Systemic Lupus ErythematosusDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07327229ATG-022Phase 1Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaOncologySep 2027
NCT05718895ATG-022Phase 1Advanced/Metastatic Solid TumorsOncologyDec 2027
NCT07732309ATG-201Phase 1Systemic Lupus ErythematosusImmunologyDec 2028
NCT07795346ATG-022Phase 3Advanced Gastric or Gastroesophageal Junction AdenocarcinomaOncologyDec 2029

Targets

CLDN18 (1) CD3 (1) CD19 (1)

Companies with the same targets

AstraZeneca Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Kali Therapeutics Astellas Vironexis Biotherapeutics Allogene Therapeutics Miltenyi Biomedicine Beijing Biotech

Companies built like this

Ganzhou Hemay Pharmaceutical Tanabe Pharma Hangzhou Sumgen Biotech Telios Pharma Molecure

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.